United Therapeutics Won Its Patent War and Liquidia Collapsed
A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting for survival, but the legal battle over Yutrepia's future is far from settled.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
A Delaware court ruling on Wednesday pushed two pulmonary hypertension drugmakers in opposite directions. Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is high blood pressure in the lung arteries of patients with scarred lung tissue. It strains the heart over time.
Liquidia (NASDAQ:LQDA) won approval for Yutrepia, an inhaled dry-powder treprostinil, for that use, and it competes directly with Tyvaso from United Therapeutics (NASDAQ:UTHR | UTHR Price Prediction). Nebulized Tyvaso sales fell 18% year over year in the second quarter, a sign the challenger was already winning patients.
Liquidia’s Own Concession Made This Ruling Decisive
A federal judge ruled that two claims of U.S. Patent 11,826,327, which Bloomberg Law reported covers inhaled dry-powder treprostinil for PH-ILD, are valid. Liquidia had already conceded that it infringes those claims, so the validity finding settled liability.
United Therapeutics rose 12.55% Wednesday to close at $541.89. Liquidia fell 57.19% to $30.26, and its lost market value is about $3.18 billion, which shows how much of the stock rested on Yutrepia’s freedom to compete.
Injunction, Damages and Appeal Are Still Undecided
United Therapeutics requested an injunction that “would restrict YUTREPIA’s availability,” and both sides must propose remedies within about a week. The court has decided neither the injunction nor damages, and final judgment remains pending.
Liquidia said its potential damages “cannot currently be reasonably estimated” and plans to ask the FDA to remove the indication from Yutrepia’s label. Chief executive Roger Jeffs said, “We respectfully disagree… fully prepared to pursue all available appellate options.”
Why the Winner Still Trades Below Its High
United Therapeutics’ 52-week high is $609.35, and the business explains the remaining gap.
Management called second-quarter results “below our expectations”. Its path to a $4 billion revenue run rate by the end of 2027 has “certainly narrowed,” leaving ralinepag and Nebulized Tyvaso in IPF, both filed with the FDA, to carry more of the growth case.
Liquidia is down 12.26% year to date but still up 33.07% over the past year. That longer record reflects a launch that ended the second quarter at an annualized run rate of about $682 million, which this week’s ruling put at risk.
What the Ruling Means for LQDA Stock
Liquidia carries the greater risk from here. Yutrepia derives most of its revenue from one product. Every open question in this case now runs against that single product, while L606, its main pipeline candidate, is only beginning Phase 3 enrollment.
United Therapeutics stands on stronger ground because it holds the valid patent and sells Remodulin, Orenitram, and Unituxin alongside Tyvaso. This view could change if the court prefers a royalty over an injunction, because that outcome would let Yutrepia keep competing.
Contact [email protected] for any questions or corrections.
Omor Ibne Ehsan is a writer at 24/7 Wall St. He is a self-taught investor with a focus on growth, cyclical, and dividend equities that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as penny stocks.
